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Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a
treatment option for selected patients with peritoneal carcinomatosis. There are limited data available on
anaesthesia management and its impact on patients’ outcome. Our aim was to retrospectively analyze and evaluate
perioperative management and the clinical course of patients undergoing CRS/HIPEC within a three-year period.
Methods: After ethic committee approval, patient charts were retrospectively reviewed for patient characteristics,
interventions, perioperative management, postoperative course, and complications. Analysis was intervention based.
Data are presented as median (range).
Results: Between 2009 and 2011, 54 consecutive patients underwent 57 interventions; median anaesthesia time
was 715 (range 370 to 1135) minutes. HIPEC induced hyperthermia with an overall median peak temperature of
38.1 (35.7-40.2)°C with active cooling. Bleeding, expressed as median blood loss was 0.8 (0 to 6) litre and large fluid
shifts occurred, requiring a total fluid input of 8.4 (4.2 to 29.4) litres per patient. Postoperative renal function was
dependent on preoperative function and the type of fluids used. Administration of hydroxyethyl starch colloid
solution had a significant negative impact on renal function, especially in younger patients. Major complications
occurred after 12 procedures leading to death in 2 patients. Procedure time and need for blood transfusion were
associated with a significantly higher risk for major complications.
Conclusions: Cytoreductive surgery with HIPEC is a high-risk surgical procedure associated with major
hemodynamic and metabolic changes. As well as primary disease and complexity of surgery, we have shown that
anaesthesia management, the type and amount of fluids used, and blood transfusions may also have a significant
effect on patients’ outcome.
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Over the last two decades, cytoreductive surgery combined
with hyperthermic intraoperative chemotherapy (CRS/
HIPEC) has become a therapeutic option for selected pa-
tients with peritoneal carcinomatosis [1]. Traditionally,
peritoneal carcinomatosis was considered a palliative incur-
able condition [2]. Sugarbaker [3], however, first described
that some of these patients may benefit from the surgi-
cal removal of all macroscopic tumor, combined with
locoregional chemotherapy [3]. Since then, CRS/HIPEC
has increasingly been used to treat patients with peri-
toneal carcinomatosis of different origin [4-11].
Strict patient selection is crucial and meticulous surgical
tumor removal is mandatory for the best clinical outcome
[9,12-14]. Thereby, longterm survival with good quality of
life is feasible [15]. As there is a learning curve when per-
forming CRS/HIPEC, centralization of the procedure to
specialized institutions is recommended [16]. Regarding an-
aesthesia management and perioperative care, experience is
limited and a consensus has yet to be found [17]. Several
authors have shown major changes in body temperature
and hemodynamics, alterations in the composition of the
blood as well as need for massive transfusion [18-21].
The aim of our study was to retrospectively analyze
anaesthesia management and postoperative course of pa-
tients undergoing CRS/HIPEC over a 3-year period since
introduction of this combined technique at the University
Hospital Zurich.Methods
After ethic committee approval (Kantonale Ethik Kom-
mission, 8090 Zurich, Switzerland; KEK# 2012–0174), all
patients operated on in a three-year period between 2009
and 2011 were included from a prospective database.
Charts were retrospectively reviewed. There were no ex-
clusion criteria. A total of 54 patients underwent 57 pro-
cedures in the time frame specified. Data analysis was
based on the number of procedures (57 = 100%).Figure 1 Time course of procedure. baseline = after induction of anaest
before HIPEC, H1 and H2 = 30 and 60 minutes after start of HIPEC, H3 = en
cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.Data collection and study variables
Anaesthesia and perioperative data were collected from
electronic patient records (KISIM™, CISTEC AG, Zurich,
Switzerland). Surgery was divided into three phases: CRS,
HIPEC, and reconstruction. Furthermore, we defined six
particular time points in order to describe the course of the
intervention (Figure 1). Data were collected on patient
characteristics, anaesthesia, intraoperative fluid, transfusion
and coagulation management, microcirculation, and body
temperature. Laboratory values and blood gas analysis were
recorded until the second postoperative day. Additionally,
the postoperative course including complications according
to the Clavien-Dindo classification were recorded. Major
complications included re-interventions under general an-
aesthesia (grade 3b), life-threatening complications requir-
ing ICU management (grade 4), and death (grade 5) [22].Cytoreductive surgery and HIPEC
All patients underwent extensive CRS followed by HIPEC.
A peritonectomy was performed as described by Sugarbaker
[3]. For HIPEC, the open abdomen technique (also
referred to as the ‘coliseum technique’) was used, allowing
the surgeons to manipulate abdominal content [23]. Inflow
and outflow tubes were connected to the hyperthermia
pump (Belmont™ Hyperthermia Pump, Belmont Instru-
ment Corporation, Billerica, United States) and 750 to
1000 ml min−1 of preheated 1.5% glucose peritoneal dialysis
solution was circulated through the abdominal cavity.
When the target temperature of between 41 and 42°C was
reached, chemotherapeutic agents were added to the solu-
tion. Three different chemotherapeutic regimens were used:
doxorubicin combined with mitomycin, doxorubicin com-
bined with cisplatin, and cisplatin combined with mitomy-
cin. HIPEC was scheduled for 60 or 90 minutes; afterwards,
the perfusate was drained and the abdominal cavity washed
out with 4000 ml of normal saline (37°C). To prevent sys-
temic hyperthermia, active cooling with forced air, cold
packs, and an infusion of cold fluids (4°C) was used.hesia but 5 minutes before start of the operation, H0 = 30 minutes
d of HIPEC, End = 5 minutes before end of the operation. CRS,
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Anaesthesia was performed according to institutional guide-
lines, with propofol or volatile anaesthetics with restrictive
transfusion management, and extensive hemodynamic mon-
itoring. Combined anaesthesia, including continuous thor-
acic epidural anaesthesia (TEA), was the technique of
choice. After surgery, patients were transferred to the ICU
or post-anaesthesia care unit (PACU). However, due to the
lack of standardization at this early stage, individual man-
agement was up to the anesthesiologist in care.
Guidance of hemodynamic and fluid therapy
To maintain end-organ perfusion, general fluid manage-
ment included a continuous baseline infusion of crystal-
loids, aiming at a urinary output of at least 0.5 (CRS
phase), 2 (HIPEC phase), and 1 (reconstruction phase) ml
kg−1 h−1, respectively. If necessary, norepinephrine was
continuously applied to keep mean arterial blood pressure
at ± 20% of baseline values. Arterial blood gas analyses
were drawn to monitor signs of tissue hypoperfusion such
as decreasing pH and base excess or increasing serum lac-
tate levels. Volume trials were initiated if defined urinary
output was not achieved and/or signs of impaired micro-
circulation were present. If applicable, the PiCCO system
[Pulsion Medical Systems, Munich, Germany] was used
for goal-directed hemodynamic and fluid management. In
a steady state, with surgical manipulation absent, the pa-
rameters of transpulmonary thermodilution and pulse
contour analysis were acquired: stroke volume variation
(SVV) of higher than 10% was considered a marker for
volume responsiveness. Changes in cardiac output, global
end-diastolic volume, and extravascular lung water in-
dexes were monitored and used as markers for further
fluid trials or vasopressors according to the manufacturer’s
hemodynamic decision model [24].
Statistical methods
Data were extracted from patient records and stored in an
Excel file (Microsoft Office 2011). Descriptive statistics are
presented as median and ranges for continuous variables
and as counts for categorical variables. Intraoperative
changes of body temperature, heart rate, mean arterial
blood pressure (MAP), and central venous pressure (CVP)
were addressed separately with mixed-effect models, ac-
counting for repeated observations over time, and adjust-
ing for the potential confounders of age, gender, and body
mass index (BMI). The Box-Cox transformed glomerular
filtration rate (GFR) measured postoperatively (day one
and two) was modelled with multiple linear regression. In-
dependent factors were preoperative GFR, blood loss,
urine output, and different intravenous fluid preparations
(Additional file 1: Table S1). For binary outcomes such as
postoperative ventilation and major (≥3b) complications,
multiple logistic regression models were used. Independentfactors are shown in Additional file 2: Table S2. Result-
ing effect sizes correspond to the logarithm of the odds
ratios (OR).
The fentanyl consumption per kg body mass, length of
postoperative ventilation, time to first bowel passage, and the
length of stay on the ICU between the groups of patients
with and without additional thoracic epidural anaesthesia
(TEA) were compared with a non-parametric Wilcoxon test
(Additional file 3: Table S3). P values of <0.05 were consid-
ered statistically significant.
All statistical procedures ignored the fact that three pa-
tients had two HIPEC interventions, and observations
were considered independent. All analyses were per-
formed with R, a software environment for statistical com-
puting and graphics [25]. The R package “reporttools” was
used for obtaining descriptive statistics, and the R package
“lme4” was used for fitting the random effects models. De-
tails of statistical analyses are presented as supplementary
data (Additional file 1: Table S1, Additional file 2: Table S2
and Additional file 3: Table S3).
Results
Data on patient characteristics and primary cancer are
presented in Table 1. A total of 54 patients underwent 57
interventions. The median BMI was 25 (range 16 to 41).
The majority of patients suffered from cancer originating
from the vermiform appendix. Other primary tumor local-
izations included colorectal and gastric cancer, mesotheli-
oma, endometrioid and ovarian cancer, and cancer arising
from the urachus and small intestine. The median oper-
ation time was 550 (255 to 995) minutes and the median
anaesthesia time was 715 (370 to 1135) minutes. The me-
dian time was 340 (95 to 790) minutes for CRS, 90 (60–
115) minutes for HIPEC, and 119 (40 to 237) minutes for
reconstruction.
Anaesthesia and monitoring
Data on intra- and peri-operative parameters are pre-
sented in Table 2. In addition to routine monitoring, ad-
vanced hemodynamic monitoring was used in 91% of all
procedures (PiCCO (Pulsion Medical Systems, Munich,
Germany) n = 48; pulmonary artery catheter (Swan-Ganz
CCOmbo, Edwards Life Sciences, Unterschleissheim,
Germany) n = 3; both techniques n = 1). General anaesthe-
sia was performed according to institutional standards,
with 79% (n = 45) being combined with a continuous thor-
acic epidural anaesthesia (TEA, ropivacaine 0.33% at be-
tween 6 and 12 ml h−1). Anaesthesia was maintained with
propofol (n = 37), sevoflurane (n = 17), or desflurane (n =
3) and supplemented with intravenous fentanyl according
to patients’ needs. Overall median fentanyl consumption
was 1.2 (range between 0.2 and 4.0) mg. Thoracic epidural
anaesthesia was maintained postoperatively with ropiva-
caine 0.2% at a rate of between 6 and 15 ml h−1.
Table 1 Patient characteristics, primary cancer, and
intraperitoneal chemotherapy
Age; years 52 (20–72)
Gender; Male:Female 23:34
Weight; kg / Height; cm 70 (44–112) / 168 (155–185)
BMI; kg m−2 25 (16–41)







Obesity (BMI >30) 8
Medication
Single ß-blocking agent 2
Single ACE-inhibitor/AT2-blocker 3
Single diuretic 0
Combination of at least two drugs 6
Other drugs2 27
None 23







54 patients underwent 57 procedures. Data are expressed as median (range)
and numbers.
ACE, angiotensin converting enzyme; ASA, American Society of
Anesthesiology; AT2, angiotensin II; BMI, body mass index (kg m−2).
1Comorbidities: cardiovascular (arterial hypertension, cardiac valve pathology,
hyperlipidemia); pulmonary (chronic bronchitis, asthma, obstructive sleep
apnea syndrome, history of acute respiratory distress syndrome, history of
pulmonary embolism); renal (one sided kidney agenesia, history of carcinoma
of the kidney, incidentaloma, chronic kidney disease); endocrine (previous
ovariectomy, medically treated hypothyroidism, diabetes mellitus); neurological
(polyneuropathy, paraesthesia, migraine, herniated vertebral disc with
neurological symptoms).
2Twenty seven patients were on additional medication: analgesics (n = 9),
proton pump inhibitors (n = 6), vitamins and supplements (n = 5), laxatives
(n = 5), hormone replacement therapy (n = 5), sedatives (n = 3), oral
antidiabetics (n = 1), chemotherapeutic agents (n = 1), antidepressants (n = 1),
antidiarrheals (n = 1), antiemetics (n = 1), acetylsalicylic acid (n = 1), statins (n = 1),
calcium channel blocker (n = 1), herbal and homeopathic preparations (n = 2).
3Other origin summarizes endometrioid cancer (n = 2), cancer of the small
intestine (n = 1) and urachus cancer (n = 1).
Table 2 Intra- and peri-operative parameters
Anaesthesia time; minutes 715 (370–1135)
Additional thoracic epidural anaesthesia 45
Advanced hemodynamic monitoring
PiCCO 48






Cumulative fentanyl dose; mg 1.2 (0.2-4.0)
Effective operation time; minutes 550 (255–995)
Length of CRS; minutes 340 (95–790)
Length of HIPEC, minutes 90 (60–115)
Length of reconstruction; minutes 119 (40–237)
Intraperitoneal chemotherapy (mg m−2)
Doxorubicin and mitomycin (15 and 15) 49
Doxorubicin and cisplatin (15 and 50) 6
Cisplatin and mitomycin (17 and 10)1 2
Transfer to ICU 53
Length of ICU stay; days 2 (1–35)
Postoperative ventilation 33
Length of postoperative ventilation; hours2 4 (1–10)
Hospital stay; days 17 (9–259)
Data presented as median (range) or numbers (n).
CRS, Cytoreductive surgery; HIPEC, hyperthermic
intraperitoneal chemotherapy.
Hemodynamic monitoring: PiCCO (Pulsion Medical Systems, Munich,
Germany); Pulmonary artery catheter (Swan-Ganz CCOmbo, Edwards Life
Sciences, Unterschleissheim, Germany).
1Reduced dose of cisplatin was given in n = 2 patients.
2Data missing in n = 6 patients.
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HIPEC induced hyperthermia with a median overall peak
temperature of 38.1 (35.7 to 40.2)°C. Body temperature
changed significantly over time (Figure 2A).
The following hemodynamic changes were found (data
not shown): heart rate significantly increased throughout
the procedure, peaked at the end of HIPEC, and remained
high until the end of surgery. Mean arterial blood pressurewas kept within 10% of baseline. Norepinephrine was ad-
ministered in 55 patients, with a median overall peak dose
of 7 (0.5 to 30) μg min−1. The median central venous pres-
sure (CVP) increased significantly during the first part of
the operation (H0 to H2).
Fluid and coagulation management
Detailed information on intraoperative fluid, transfusion,
and coagulation management is shown in Table 3. Coagula-
tion parameters were analyzed using routine laboratory test-
ing and bedside rotational thromboelastometry (ROTEM™,
Tem Innovations GmbH, Munich, Germany). One patient
with a bleeding diathesis suffering from a known hereditary
factor VII deficiency required recombinant factor VIIa. Post-
operatively, seven patients showed thrombocytopenia
(<50000 μl−1) and nine patients developed leukocytopenia
(<4000 μl−1) on median postoperative day three (range 0 to
12). Preoperative median hemoglobin values were 127
(range 97 to 164) g l−1, falling to 82 (range 46 to 125) g
l−1 intraoperatively. At the end of surgery, the median
Figure 2 Intraoperative course of temperature and lactate. A. Change in temperature compared to baseline: the horizontal line set at 0 is
representing baseline. If the 95% confidence interval presented for each time point does not overlap with baseline, temperature differs
significantly from baseline (P <0.05). A mixed-effect model describing the effect of phase was used. B. Boxplot describing arterial lactate levels
throughout the intervention. Baseline = after induction of anaesthesia but before start of the operation, H0 = 30 minutes before HIPEC, H1 and
H2 = 30 and 60 minutes after start of HIPEC, H3 = end of HIPEC, End = 5 minutes before end of the operation. HIPEC, hyperthermic
intraperitoneal chemotherapy.
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remained low until postoperative day two.
Renal function and metabolic alterations
Details on urine output are summarized in Table 3. To
maintain urine output during HIPEC, fluids in combin-
ation with IV diuretics were administered to 35 patients
(61%). Furosemide was administered to 25 patients (44%),
mannitol was administered 20 patients (35%) and 10 pa-
tients (18%) received both drugs. Median doses were 10
(range 2.5 to 20) mg for furosemide and 20 (range 20 to
40) g for mannitol. Two patients became oliguric (urine
output <0.5 ml kg−1 h−1) without clinical relevance. Pre-
operative GFR had an impact on postoperative GFR as the
higher the preoperative value, the higher the postoperative
value (P <0.001) (Additional file 1: Table S1). Intraopera-
tive blood loss and urine output had no significant impact
on postoperative GFR (Additional file 1: Table S1). Re-
garding the type of fluid administered, we did not find any
negative effects of crystalloids on renal function. However,
the amount of hydroxyl-ethyl starch (HES) given had a
significant negative effect on postoperative GFR in pa-
tients younger than 60 years (P <0.001) (Additional file 1:
Table S1). Three patients (5%) suffered from acute deteri-
oration of renal function during their hospital stay.
During surgery, pH and base excess decreased signifi-
cantly. The lowest values were reached at the end of
HIPEC (stage H3) with a median pH of 7.38 (range 7.27 to
7.53) and a median base excess of −4.3 (range −10.8 to
0.6) mEql l−1. Figure 2B describes plasma lactate levels in-
versely increasing throughout the intervention. Hypergly-
cemia, defined as a blood glucose level of >10 mmol l−1,
was present in 42 patients (74%). Sixteen patients (28%)required insulin therapy intraoperatively, although only
one of the patients was a known diabetic.
Postoperative course
The median length of hospital stay was 17 (range 9 to
259) days and the median length of ICU stay was 2 (range
1 to 35) days. A total of 33 ICU patients were ventilated
on ICU arrival. There was a positive correlation between
the amount of opioids administered intraoperatively and
the probability for postoperative mechanical ventilation
(P <0.05, Additional file 2: Table S2). The overall duration
of surgery (P <0.001, Figure 3A) and the amount of blood
loss (P <0.05, Figure 3B) also had a significant impact on
the need for mechanical respiratory support (Additional
file 2: Table S2). Comparing the postoperative course of
patients with and without TEA, we found a significant dif-
ference in the amount of fentanyl given - patients with
combined anaesthesia needed less fentanyl (P <0.001). We
could not show any difference in the length of postopera-
tive ventilation (P = 0.56), length of stay on the ICU (P =
0.52), nor time to first bowel passage (P = 0.73) between
the two groups (Additional file 3: Table S3). However, the
sample was strongly unbalanced, as sample sizes in the
two groups were very different and data were missing. Re-
garding anaesthesia-related complications, one patient de-
veloped an epidural abscess after TEA, requiring operative
decompression seven days after insertion.
Major surgical complications (≥3b)
Major complications according to the Clavien-Dindo
classification (grade 3b to 5) [22] occurred after 12 inter-
ventions, and 2 patients (4%) died. The first patient, a
46-year-old man, was suffering from adenocarcinoma of





Crystalloids; ml 57 5900 (2200–19100)
Crystalloids per hour; ml h−1 473 (187–1041)
Colloids; ml 56 2500 (500–14500)
Colloids per hour; ml h−1 189 (52–852)
HES 130/0.4; ml 14 1000 (500–2500)
Gelatine; ml 51 2500 (500–12000)
Blood products and coagulation
factor concentrates
PRBC; n 16 4 (1–10)
FFP; n 3 6 (4–8)
Thrombocytes; n 4 1 (1–2)
Fibrinogen; g 21 4 (2–22)
Prothrombin complex concentrate; IU 9 1000 (400–2000)
Factor XIII; IU 13 1500 (1250–4000)
Factor VIII-vWF; IU 1 1000
Recombinant factor VII; μg 1 1000
Total input; ml 57 8200 (4200–29400)
Total hourly input; ml h−1 697 (363–1603)
Output
Blood loss; ml 57 800 (0–6000)
Urine; ml 57 1460 (330–3970)
Urine per hour, CRS; ml h−1 94 (34–350)
Urine per hour, HIPEC; ml h−1 220 (47–787)
Urine per hour, reconstruction; ml h−1 183 (33–631)
Ascites; ml 11* 1500 (100–3000)
Total output; ml 57 2670 (530–10780)
Total hourly output; ml h−1 218 (58–729)
54 patients underwent 57 procedures. Data are expressed as median (range)
and numbers (n).
Fluids: Crystalloids = Ringerfundin™ (B.Braun Medical AG, Melsungen,
Germany); Colloids = gelatine (Physiogel™ balanced, B. Braun Medical AG,
Melsungen, Germany) and HES 130/0.4 (Tetraspan™, B. Braun Medical AG,
Melsungen, Germany). PRBC and thrombocytes were applied in units of 300
ml, FFP in units of 280 ml.
Coagulation factor concentrates: Fibrinogen (Hemocomplettan P™, CSL
Behring AG, Bern, Switzerland), Prothrombin complex concentrate (PCC,
Beriplex P/N™, CSL Behring AG, Bern, Switzerland), Factor XIII (Fibrogammin
P™, CSL Behring AG, Bern, Switzerland), Factor VIII-vWF (Hemate P™, CSL
Behring AG, Bern, Switzerland), recombinant activated Factor VIIa
(Novoseven™, Novo Nordisk Pharma AG, Kusnacht, Switzerland).
*data missing in 46 patients.
HES, hydroxyethyl starch; IU, international units; PRBC, packed red blood cells;
FFP, fresh frozen plasma; vWF, von Willebrand factor.
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esophagogastrectomy. The effective operation time was
800 minutes. The patient required 8 units of packed red
blood cells (PRBC), 500 IU prothrombin complex con-
centrate (PCC), and 10 g fibrinogen due to extensive
bleeding (lowest hemoglobin level was 47 g l−1) intraop-
eratively. After an uneventful initial recovery, the patientdied 17 days later from hemorrhagic shock and multior-
gan dysfunction syndrome. The second patient, a 57-year-
old man, was suffering from a mucinous adenocarcinoma
of the appendix with peritoneal carcinomatosis. The ef-
fective operation time was 995 minutes. The surgery was
complex and the patient required 4 units of PRBC (lowest
hemoglobin level was 71 g l−1), 1 unit of platelets and sev-
eral coagulation factor concentrates (14 g fibrinogen,
2500 IU factor XIII, 1000 IU PCC and 1000 IU factor
VIII). After a long postoperative course with several re-
interventions the patient died after 259 days from septic
shock.
The rate of major surgical complications increased sig-
nificantly with longer operation (Figure 3C) and anaesthe-
sia time (both P <0.01; Figure 3D, Additional file 2: Table
S2). We found the receipt of a blood transfusion to be an
independent risk factor for major complications (P <0.05;
Additional file 2: Table S2). The lowest overall hemoglobin
values (describing the amount of blood loss) correlated
with a trend towards an increased risk of major complica-
tions (P = 0.05, Additional file 2: Table S2). The adminis-
tration of coagulation factor concentrates did not increase
the risk of major complications, nor did the presence of
obesity, arterial hypertension, carcinoma of the appendix,
or preoperative anaemia (Additional file 2: Table S2).
Discussion
Data on anaesthesia management and the outcome of 57
consecutive patients undergoing combined CRS/HIPEC
were retrospectively collected and analyzed at our hos-
pital. In addition to the individual surgical complexity,
we have shown that several factors may affect patients’
outcome, such as the type and amount of resuscitation
fluids used, as well as blood transfusions.
Cytoreductive surgery with HIPEC is a long-lasting, ab-
dominal surgical procedure (median anaesthesia time
715 minutes) with additional hyperthermia and intraoper-
ative chemotherapy. Extensive bleeding and fluid shifts
may occur. Therefore, fluid status and cardiac function
were continuously assessed with advanced hemodynamic
monitoring in most of our patients.
Currently the type and amount of fluid administration is
subject to debate [26-28]. Our fluid management consisted
of both crystalloids and colloids. In addition to crystalloids,
51 patients received gelatine and 14 were also given HES,
in a ratio of approximately 2.5:1. At the time of observation,
studies on the potentially harmful effects of HES prepara-
tions in septic ICU patients had not yet been published
[29,30]. Our data are in accordance with these publications:
HES administration had a significant negative impact on
renal function, especially in younger patients.
Maintaining renal function and prevention of injury is
critical for obtaining the best perioperative outcome [31].
Known risk factors for acute renal injury are hypovolemia,
Figure 3 Operation time, blood loss, and anaesthesia time and their effects on the need for postoperative ventilation and major
surgical complications. A and B. The multiple logistic regression model describes the need for postoperative respiratory assistance (vertical axis:
0 = no assistance, 1 = assistance needed) depending on operation time (minutes) and blood loss (ml). The longer the operation (P <0.01) and
the higher the blood loss (P <0.05), the higher the need was for postoperative ventilation. C and D. Major complications (≥3b according to the
Clavien-Dindo classification) on the vertical axis (0 for complications <3b, 1 for ≥3b) are plotted against operation time (minutes) or anaesthesia
time (minutes) on the horizontal axis. The longer the operation (P <0.01) and the longer anaesthesia time (P <0.01), the higher the incidence of
major complication was. Data are corrected for BMI and age.
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fusions, and systemic inflammation [32]. Hemodynamic
optimization (optimizing cardiac output, tissue perfusion,
and oxygenation) is highly recommended to prevent renal
injury. The goal is to maintain the effective circulating
blood volume by careful fluid and transfusion manage-
ment, vasopressors, and inotropes [33]. Most authors rec-
ommend liberal fluid regimens [14,18,34]. Our patients
received approximately 10 ml kg−1 hr−1 of fluids and lost
3 ml kg−1 hr−1 (Additional file 3: Table 3). The amount of
fluids given was guided by hemodynamic parameters,
blood gas analyses, and urinary output. Most patients were
given vasopressors to maintain MAP and, although the
benefit of its application is questionable, 35 patients were
given IV diuretics to force diuresis during HIPEC [33]. In
fact, there is no evidence that a single pharmacological
intervention during surgery protects the kidneys from
damage [31,35].
Our data suggests that the need for a blood transfusion
is associated with an increased risk for major complica-
tions (grade ≥3b according to the Clavien-Dindo classifica-
tion [22]). The amount of bleeding showed a trend
towards major complications (P = 0.05). It is standard pro-
cedure for both the surgical and the anaesthesia team to
assess and estimate blood loss at the end of surgery.However, differences between both estimates result in in-
consistent documentation. Alternatively, the decrease in
hemoglobin concentration can be used as an indicator for
blood loss. Both methods are widely used in clinics but are
known to be of limited accuracy, tending to underestimate
actual blood loss [36]. For future studies it might be useful
to refer to a superior, validated blood loss score, taking
into account the hemoglobin concentration of suction
fluid [36].
Exposure to blood transfusions is associated with an in-
creased morbidity and mortality in surgical oncology
[37,38]. It is therefore critical to control surgical bleeding
and to diagnose and correct coagulopathy early. Goal-
directed, aggressive treatment using algorithms and point-
of-care coagulation testing is recommended [37]. In our
study, 28% of patients required intraoperative blood trans-
fusions and 37% of patients were given coagulation factor
concentrates. In contrast to other centers, routine FFP ad-
ministration is not the first-line treatment for established
coagulopathy at our institution [17]. Only 5% of patients re-
ceived FFPs compared to 45% described in the literature
[17,18]. The pathophysiology of coagulopathy in patients
undergoing CRS/HIPEC is not completely understood
[14,17]. Besides bleeding, consumption, and dilution, pa-
tients are exposed to extreme changes in body temperature
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osis, and calcium depletion (40% of our patients required
calcium supplementation).
The use of TEA is recommended for patients under-
going CRS/HIPEC to provide optimal pain therapy, to
reduce length of postoperative ventilation and pulmon-
ary complications, and to allow for early mobilization
(getting people moving as soon as possible) [14,34].
Critics underline the potential risk of hemodynamic
instability, epidural hematoma, and infectious compli-
cations due to massive bleeding, impaired coagulation,
and chemotherapy-induced immunodeficiency [39-41].
Recently an incidence ratio for infectious complica-
tions of 1:2139 has been reported [17]. One of our pa-
tients suffered from an epidural abscess with the need
for an operative decompression seven days after place-
ment. To prevent infections we recommend to limit the
postoperative use of epidural analgesia to a maximum of
five days and to visit patients with TEA daily. Despite the
frequent use of TEA, only 28% of CRS/HIPEC centers de-
scribe their pain management as excellent [17]. Most of
our patients received TEA for intra- and post-operative
analgesia, and we found a significant opiod-sparing effect.
However, unlike previous publications, we could not show
that TEA was associated with a reduced length of postop-
erative ventilation and ICU stay, nor shortened time to
first bowel passage [18].
The present observational study has some limitations.
The anaesthesia management of patients did not follow
strict protocols and there were no predefined exclusion
criteria for the study. Furthermore, data were collected
retrospectively and some data were missing due to ab-
sent documentation, compromising data analysis and re-
ducing power of statistical conclusions.
Conclusions
Taken together, combined CRS/HIPEC is a high-risk sur-
gical procedure associated with major hemodynamic and
metabolic changes. It requires coordinated and patient-
centred anaesthetic management, including meticulous
monitoring of the different physiological systems of the
body. Besides primary disease and complexity of surgery,
we have shown that the type and amount of fluids used,
blood transfusions, and anaesthetic management may have
an impact on patients’ outcome. To further differentiate fac-
tors affecting the outcome, prospective randomized con-
trolled trials are highly warranted in this field.Additional files
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